Bruce Imbert News Today

/PRNewswire/ -- Tempero Bio has recently been awarded a grant expected to total $5.3 million over two years from the National Institute on Drug Abuse (NIDA),...

BOSTON--(BUSINESS WIRE)--Dec 15, 2021--

Pear Therapeutics and Prescryptive Health Announce Formulary Coverage for Prescription Digital Therapeutics reSET® & reSET-O® for the Treatment of Substance and Opioid Use Disorders By Staff 2 seconds ago Prescryptive Health, a health intelligence platform focused on improving the prescription drug market and the pharmacy experience, teams with Pear to make innovative prescription digital therapeutics (PDTs) accessible to its members in recovery. Prescryptive Health will offer and administe...

Company adds a leading national Integrated Delivery Network (IDN) as a strategic investor. The financing supports Pear’s continued efforts to expand patient access for its portfolio of Prescription Digital Therapeutics (PDTs), including reSET®, reSET-O® and Somryst® treating addiction and insomnia conditions, respectively. BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced the second closing of its Series D financing. The s...

News Category Global Banking & Finance Reviews Groups Recover Together Teams with Pear Therapeutics to Provide People in Recovery Access to Innovative Treatment Groups Recover Together Teams with Pear Therapeutics to Provide People in Recovery Access to Innovative Treatment Opioid use disorder (OUD) is often an isolating experience and with COVID-19-related social distancing, fostering recovery is challenging. Recover Together, Inc. (Groups), a leading outpatient treatment provider serving ind...

Pear Therapeutics Announces Publication of Economic Analysis Assessing the Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder (OUD) By Staff 4 months ago reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD). New economic analysis showed reSET-O to be cost-effective compared to treatment-as-usual alone over 12 weeks, and to have economic dominance when contingency management (CM) was included as part of t...